Economy

Novo Nordisk launches oral version of Wegovy weight-loss drug in U.S.

Illustration for: Novo Nordisk launches oral version of Wegovy weight-loss drug in U.S.
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

Jan 5, 2026

THE BARE STORY

Novo Nordisk has released a pill version of its weight-loss drug Wegovy in the United States, introducing the first oral GLP-1 medication for obesity to the market. The Danish pharmaceutical company announced the rollout on Monday, following approval from the Food and Drug Administration (FDA) in December. The daily tablet contains semaglutide, the same active ingredient found in the company’s injectable treatments, Wegovy and Ozempic.

According to Novo Nordisk, the pill functions by mimicking a gut hormone to suppress appetite and is intended for use in conjunction with diet and exercise. Ed Cinca, a senior vice president at the company, described the product as a significant innovation that opens new possibilities for patients. Clinical trial data cited by the manufacturer indicated that users lost between 14% and 17% of their body weight on average. The FDA has also cleared the treatment to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults with obesity and established heart disease.

The medication is available at pharmacies and through telehealth providers, with a starting dose of 1.5 milligrams priced at $149 per month for cash-paying patients. Higher doses are listed at prices ranging up to $299 per month. This pricing structure positions the oral drug as a lower-cost alternative to injectable GLP-1 treatments, which frequently carry list prices of approximately $1,000 per month.

The launch establishes an early lead for Novo Nordisk in the oral weight-loss sector ahead of competitor Eli Lilly, whose rival pill is currently under regulatory review. Novo Nordisk noted that the pill comes with side effects similar to the injectable version, including nausea and diarrhea, and patients are instructed to wait 30 minutes after taking the medication before eating or drinking.

Same Facts. Different Perspectives.

Two AI models. Two viewpoints. One factual foundation.

Perspective by Grok

• Usage requires adherence to specific administration rules Patients prescribed the oral medication are instructed to wait 30 minutes after taking the tablet before eating or drinking. This daily requirement is a necessary component of the treatment plan, which is intended to be used in conjunction with diet and exercise.

• Physical side effects mirror those of injectable versions Novo Nordisk noted that the oral pill comes with side effects similar to the company’s injectable treatments. Patients utilizing the new medication may experience adverse physical reactions including nausea and diarrhea.

• Market exclusivity faces looming competition While this launch establishes an early lead for Novo Nordisk in the oral weight-loss sector, rival pharmaceutical company Eli Lilly is developing a competing product. The article reports that Eli Lilly’s rival pill is currently under regulatory review, indicating future competition in this specific market segment.

How it may affect me

As a U.S. reader:

• Cash-paying patients may access this medication for $149 to $299 per month, providing a lower-cost alternative to injectable treatments that frequently list for approximately $1,000.

• If prescribed this daily tablet, you must follow strict administration rules, including waiting 30 minutes after dosing before eating or drinking to ensure the medication functions correctly.

• Users can expect average weight loss between 14% and 17% alongside reduced cardiovascular risks, though physical side effects like nausea and diarrhea mirror those of injectable versions.

• You can obtain this medication through pharmacies or telehealth providers immediately, with additional options potentially emerging as competitor Eli Lilly has a rival pill under regulatory review.

Read the story at

Note: All TheBareNews content is AI-generated. For additional context, reporting, and updates, you are invited to explore the news outlets linked above.